Inflammatory Response of Ischemic Tolerance in Circulating Plasma : Preconditioning-Induced by Transient Ischemic Attack (TIA) Phenomena in Acute Ischemia Patients (AIS)
Colàs-Campàs, Laura (Institut de Recerca Biomèdica de Lleida)
Farre, Joan (Hospital Universitari Arnau de Vilanova)
Mauri-Capdevila, Gerard (Hospital Universitari Arnau de Vilanova)
Molina-Seguín, Jessica (Institut de Recerca Biomèdica de Lleida)
Aymerich, Núria (Complejo Hospitalario de Navarra)
Ois, Angel (Hospital del Mar (Barcelona, Catalunya))
Roquer González, Jaume (Hospital del Mar (Barcelona, Catalunya))
Tur, Silvia (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
García-Carreira, Maria del Carmen (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Martí-Fàbregas, Joan (Institut d'Investigació Biomèdica Sant Pau)
Cruz-Culebras, Antonio (Hospital Universitario Ramón y Cajal (Madrid))
Segura, Tomás (Complejo Hospitalario Universitario de Albacete)
Arque, Gloria (Institut de Recerca Biomèdica de Lleida)
Purroy, Francisco (Hospital Arnau de Vilanova (Lleida, Catalunya))
Universitat Autònoma de Barcelona
Date: |
2020 |
Abstract: |
Ischemic tolerance (IT) refers to a state where cells are resistant to the damaging effects caused by periods of ischemia. In a clinical scenario, the IT phenomenon would be activated by a recent transient ischemic attack (TIA) before an ischemic stroke (IS). The characterization of inflammatory protein expression patterns will contribute to improved understanding of IT. A total of 477 IS patients from nine hospitals, recruited between January 2011 and January 2016, were included in the current study and divided in three groups: 438 (91. 9%) patients without previous TIA (group 1), 22 (4. 6%) patients who suffered TIA 24 h before IS (group 2), and 17 (3. 5%) patients who suffered TIA between 24 h and 7 days prior to IS (group 3). An inflammatory biomarker panel (IL-6, NT-proBNP, hsCRP, hs-Troponin, NSE, and S-100b) on plasma and a cytokine antibody array was performed to achieve the preconditioning signature potentially induced by TIA phenomena. Primary outcome was modified rankin scale (mRs) score at 90 days. Recent previous TIA was associated with better clinical outcome at 90 days (median mRS of group 1: 2. 0 [1. 0-4. 0]; group 2: 2. 0 [0. 0-3. 0]; group 3: 1. 0 [0-2. 5]; p = 0. 086) and smaller brain lesion (group 1: 3. 7 [0. 7-18. 3]; group 2: 0. 8 [0. 3-8. 9]; group 3: 0. 6 [0. 1-5. 5] mL; p = 0. 006). All inflammation biomarkers were down regulated in the groups of recent TIA prior to IS compared to those who did not suffer a TIA events. Moreover, a cytokine antibody array revealed 30 differentially expressed proteins between the three groups. Among them, HRG1-alpha (Fold change 74. 4 between group 1 and 2; 74. 2 between group 1 and 3) and MAC-1 (Fold change 0. 05 between group 1 and 2; 0. 06 between group 1 and 3) expression levels would better stratify patients with TIA 7 days before IS. These two proteins showed an earlier inflammation profile that was not detectable by the biomarker panel. Inflammatory pathways were activated by transient ischemic attack, however the period of time between this event and a further ischemic stroke could be determined by a protein signature that would contribute to define the role of ischemic tolerance induced by TIA. |
Grants: |
Instituto de Salud Carlos III PI17-01725 Ministerio de Economía y Competitividad PI14/01574
|
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Biomarker (BM) ;
Endogenous neuroprotection ;
Ischemic preconditioning ;
Ischemic stroke ;
Plasma ;
Transient ischemic attack (TIA) |
Published in: |
Frontiers in neurology, Vol. 11 (29 2020) , p. 552470, ISSN 1664-2295 |
DOI: 10.3389/fneur.2020.552470
PMID: 33192985
The record appears in these collections:
Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Parc Taulí Research and Innovation Institute (I3PTResearch literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Institut de Recerca Sant PauArticles >
Research articlesArticles >
Published articles
Record created 2023-10-14, last modified 2024-06-11